| Domain | Established finding | Suggested ontology term(s) | Evidence type/strength | Key source |
|---|---|---|---|---|
| Disease identity | Growth restriction, hypoplastic kidneys, alopecia, and distinctive facies is an ultra-rare congenital multisystem Mendelian syndrome associated with ZPR1 deficiency. | **MONDO:0859146**; suggested synonym: *ZPR1-associated growth-restriction syndrome* | Authoritative disease-level association supported by one small human case series | Open Targets maps the exact disease label to MONDO:0859146 and ZPR1 (pqac-00000001) |
| Causal gene and inheritance | Biallelic **ZPR1** variation causes the syndrome; segregation in reported families supports autosomal-recessive inheritance. Parents and unaffected siblings were heterozygous carriers. | Suggested: ZPR1; autosomal recessive inheritance (**HP:0000007**) | Strong human genetic evidence, but based on four affected children from three families | Ito et al., 2018, PMID 29851065; summarized in the 2024 analysis (pqac-00000008) |
| Pathogenic variant | Reported causal variant: homozygous **ZPR1 c.587T>C (p.Ile196Thr)**, dbSNP **rs368697578**; germline missense variant in the A-domain involved in eEF1A interaction. | Suggested: sequence variant; missense variant (**SO:0001583**); germline variant | Strong segregation plus patient-cell functional evidence; ClinVar-listed, although current laboratory classification should be verified directly | Ito et al., 2018; variant/domain data (pqac-00000008, pqac-00000010) |
| Growth phenotype | Prenatal and postnatal growth restriction is a defining manifestation; the cellular phenotype resembles mechanisms implicated in primordial dwarfism. | Suggested HPO: intrauterine growth restriction (**HP:0001511**), postnatal growth retardation (**HP:0008897**), short stature (**HP:0004322**) | Human clinical evidence; exact patient-level frequencies and longitudinal growth curves unavailable in retrieved evidence | Four-child case series summarized in 2024 (pqac-00000002, pqac-00000008) |
| Renal phenotype | Hypoplastic kidneys and kidney dysfunction are core manifestations. Detailed laterality, nephron pathology, laboratory values, chronic-kidney-disease stages, and progression rates were not available. | Suggested HPO: renal hypoplasia (**HP:0000089**), abnormal renal function (exact term to validate); suggested UBERON: kidney | Human clinical evidence; small cohort and incomplete natural history | Ito et al., 2018 title and subsequent summary (pqac-00000008, pqac-00000015) |
| Hair/ectodermal phenotype | Congenital or inborn alopecia is characteristic. Hair-follicle histopathology and progression were not reported in the retrieved evidence. | Suggested HPO: alopecia (**HP:0001596**), congenital alopecia (exact child term to validate); suggested UBERON: hair follicle | Human clinical evidence; frequency not independently quantifiable beyond the defining case-series phenotype | Ito et al., 2018; 2024 summary (pqac-00000002, pqac-00000008) |
| Craniofacial and neurologic phenotype | Distinctive craniofacial features occur; reported associated findings include microcephaly, moderate intellectual disability, developmental delay, optic-nerve atrophy, and sensorineural hearing loss. | Suggested HPO: abnormal facial shape (**HP:0001999**), microcephaly (**HP:0000252**), intellectual disability (**HP:0001249**), global developmental delay (**HP:0001263**), optic atrophy (**HP:0000648**), sensorineural hearing impairment (**HP:0000407**) | Human clinical evidence, but individual-feature denominators are unavailable | Human syndrome findings summarized from Ito et al. (pqac-00000007, pqac-00000008) |
| Protein dysfunction | p.Ile196Thr lies in the hydrophobic core/A-domain and destabilizes ZPR1; patient fibroblasts reportedly contained little or no detectable ZPR1 because the misfolded protein was degraded by the proteasome. A 2024 FoldX analysis predicted a destabilizing ΔΔG of approximately 2.3 kcal/mol. | Suggested GO: protein folding, proteasomal protein catabolic process, regulation of protein stability; suggested cellular components: cytoplasm, nucleus, nucleolus | Patient-cell evidence plus computational structural support; degradation mechanism is stronger than purely in-silico predictions but needs replication | Ito et al. functional findings and 2024 modeling (pqac-00000003, pqac-00000007, pqac-00000010) |
| Cell-cycle mechanism | Mutant patient fibroblasts showed impaired progression beyond G1, with very few cells reaching late S or G2/M. Reduced proliferative capacity is the most direct demonstrated mechanism linking ZPR1 deficiency to generalized developmental growth failure. | Suggested GO: cell-cycle progression (**GO:0007049**), G1/S transition of mitotic cell cycle (**GO:0000082**), cell proliferation (**GO:0008283**); suggested CL: fibroblast (**CL:0000057**) | Direct patient-derived-cell functional evidence; organ-specific causal links remain inferred | Ito et al. findings summarized in the 2024 analysis (pqac-00000003, pqac-00000008, pqac-00000017) |
| Molecular pathway | ZPR1 normally participates in eEF1A-, EGFR-, SMN-, and RNA-polymerase-II-related complexes, translocating from cytoplasm to nucleus/nucleolus in proliferating cells. Disruption of ZPR1–eEF1A interaction by p.Ile196Thr is plausible but not directly demonstrated for every affected tissue. | Suggested GO: protein binding, nucleolar localization, transcription regulation, ribonucleoprotein-complex assembly; suggested cellular components: nucleolus (**GO:0005730**), nucleus (**GO:0005634**), cytoplasm (**GO:0005737**) | Established general ZPR1 biology; syndrome-specific pathway assignment remains partly inferred | Structural and localization literature summarized in 2024 (pqac-00000008, pqac-00000011) |
| Diagnosis | Diagnosis rests on recognition of the congenital phenotype plus molecular confirmation of biallelic ZPR1 variants. Exome or genome sequencing is preferable when the phenotype is nonspecific; targeted familial testing can confirm segregation. Renal ultrasound/function tests, audiology, ophthalmology, growth, and developmental assessments define organ involvement. | Suggested NCIT: Whole Exome Sequencing, Whole Genome Sequencing, Genetic Testing, Ultrasonography, Audiologic Test; suggested HPO-driven phenotyping | Genetic-testing strategy is a rational implementation based on discovery by exome sequencing; no formal syndrome-specific diagnostic criteria or guideline | Proband exome and segregation evidence (pqac-00000008); limited formal characterization acknowledged in 2024 (pqac-00000017) |
| Epidemiology and population data | Only four affected children from three New Mexican Hispanic ancestral families were initially reported; a Rio Grande Valley founder effect/endogamy was suggested but not proven. A 2024 preprint reported predicted damaging heterozygous ZPR1 variants in 0.04%–0.34% of ancestry groups, but these figures are **not** disease prevalence or validated carrier frequency for p.Ile196Thr. | Suggested epidemiology annotation: ultra-rare disease; founder variant hypothesis | Very limited human ascertainment; population estimates are computational and should not be used as clinical penetrance estimates | Human families and founder hypothesis (pqac-00000008); gnomAD-based computational statistics (pqac-00000010, pqac-00000013) |
| Management and trials | No disease-modifying therapy, syndrome-specific management guideline, or relevant clinical trial was identified. Care is supportive and organ-directed, with renal, growth/nutrition, hearing, vision, neurodevelopmental, and genetic-counseling follow-up. ZPR1 overexpression studies in spinal muscular atrophy are not treatment evidence for this syndrome. | Suggested NCIT: Supportive Care, Genetic Counseling, Audiologic Rehabilitation, Physical Therapy, Occupational Therapy; exact NCIT identifiers to validate | Expert extrapolation from manifestations; no syndrome-specific intervention evidence | Literature and trial-gap assessment (pqac-00000014, pqac-00000015, pqac-00000018, pqac-00000021) |
| Prognosis | The published phenotype includes increased early mortality, but survival rates, causes of death, renal-failure risk, and life expectancy have not been quantified. Lifelong multisystem morbidity is likely, but the course cannot be reliably estimated from four reported patients. | Suggested HPO/course annotations: congenital onset, chronic course, early mortality (exact terms to validate) | Weak-to-moderate natural-history evidence because of extremely small sample and absent longitudinal cohort | Clinical summary of the original families (pqac-00000002, pqac-00000015) |
| Models and comparative evidence | No natural veterinary disease or p.Ile196Thr syndrome-specific knock-in model was identified. Zpr1-deficient mice show neurodegeneration, facial and spinal motor-neuron loss, axon retraction, and microtubule disruption; these models establish biological necessity but incompletely reproduce the human renal–hair–growth syndrome. | Suggested taxa: *Mus musculus* (**NCBI Taxon:10090**); suggested CL: motor neuron (**CL:0000100**); suggested GO: neuron death, axon maintenance, microtubule organization | Experimental mouse evidence, indirect for this syndrome; SMA rescue models are mechanistic comparators only | ZPR1-deficient mouse findings and limitations (pqac-00000004, pqac-00000014) |


*Table: Compact ontology-ready summary of established findings, evidence strength, and major knowledge gaps for MONDO:0859146. Ontology mappings marked “suggested” require curator validation before database ingestion.*